Literature DB >> 20603649

Castleman's disease--a two compartment model of HHV8 infection.

Klaus-Martin Schulte1, Nadia Talat.   

Abstract

Castleman's disease is a primary infectious disease of the lymph node that causes local symptoms or a systemic inflammatory syndrome. Histopathology reveals a destroyed lymph node architecture that can range from hyaline-vascular disease to plasma-cell disease. Viral interleukin 6 (vIL-6) produced during the replication of human herpesvirus type 8 (HHV8) is the key driver of systemic inflammation and cellular proliferation. Stage progression of Castleman's disease results from switches between viral latency and lytic replication, and lymphatic and hematogenous spread. Multicentric plasma-cell disease in HIV-1 patients is associated with HHV8 infection. Polyclonal plasmablast proliferation escapes control in the germinal center with eventual malignant transformation into non-Hodgkin lymphoma. Surgery produces excellent results in unicentric disease, while multicentric disease responds to anti-CD20 therapy or IL-6 and chemotherapy. Lymphovascular endothelium and naive B cells are infectious reservoir-opening options for antiangiogenic and anti-CD19 strategies to enhance outcomes in patients with systemic disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20603649     DOI: 10.1038/nrclinonc.2010.103

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


  118 in total

1.  Lymphnodal hamartoma versus thymic choristoma of pulmonary hilum.

Authors:  M R ABELL
Journal:  AMA Arch Pathol       Date:  1957-11

Review 2.  The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care.

Authors:  Corey Casper
Journal:  Br J Haematol       Date:  2005-04       Impact factor: 6.998

Review 3.  Castleman disease.

Authors:  Angela Dispenzieri
Journal:  Cancer Treat Res       Date:  2008

Review 4.  Germinal centers.

Authors:  I C MacLennan
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

5.  Focal Castleman disease of the lung: MRI findings.

Authors:  F Ferrozzi; G Tognini; E Spaggiari; P Pavone
Journal:  Clin Imaging       Date:  2001 Nov-Dec       Impact factor: 1.605

6.  Angiomatous lymphoid hamartoma. Report of five cases with a review of the literature.

Authors:  K S Tung; L J McCormack
Journal:  Cancer       Date:  1967-04       Impact factor: 6.860

7.  [Kaposi's disease and HHV8: a new model of virus-induced tumorigenesis].

Authors:  C Pellet; C Lebbé
Journal:  Pathol Biol (Paris)       Date:  2000-07

8.  Interleukin-6 gene expression in Castleman's disease.

Authors:  M B Leger-Ravet; M Peuchmaur; O Devergne; J Audouin; M Raphael; J Van Damme; P Galanaud; J Diebold; D Emilie
Journal:  Blood       Date:  1991-12-01       Impact factor: 22.113

9.  18F-FDG PET/CT in the evaluation of POEMS syndrome.

Authors:  M A Albertí; S Martinez-Yélamos; A Fernandez; A Vidaller; J A Narváez; L M Cano; C Gamez; J A Martinez-Matos
Journal:  Eur J Radiol       Date:  2009-07-05       Impact factor: 3.528

10.  Brief communication: rituximab in HIV-associated multicentric Castleman disease.

Authors:  Mark Bower; Tom Powles; Sarah Williams; Tom Newsom Davis; Mark Atkins; Silvia Montoto; Chloe Orkin; Andy Webb; Martin Fisher; Mark Nelson; Brian Gazzard; Justin Stebbing; Peter Kelleher
Journal:  Ann Intern Med       Date:  2007-12-18       Impact factor: 25.391

View more
  16 in total

1.  HHV8-related lymphoid proliferations: a broad spectrum of lesions from reactive lymphoid hyperplasia to overt lymphoma.

Authors:  Blanca Gonzalez-Farre; Daniel Martinez; Monica Lopez-Guerra; Marc Xipell; Ester Monclus; Jordina Rovira; Felipe Garcia; Armando Lopez-Guillermo; Luis Colomo; Elias Campo; Antonio Martinez
Journal:  Mod Pathol       Date:  2017-01-13       Impact factor: 7.842

2.  Surgical Management of Unicentric Castleman's Disease in the Abdomen.

Authors:  Min-Sang Kim; Jae-Kyun Ju; Young Kim
Journal:  Ann Coloproctol       Date:  2014-04-25

Review 3.  Castleman's disease: systematic analysis of 416 patients from the literature.

Authors:  Nadia Talat; Klaus-Martin Schulte
Journal:  Oncologist       Date:  2011-07-17

Review 4.  The role of IL-6 in host defence against infections: immunobiology and clinical implications.

Authors:  Stefan Rose-John; Kevin Winthrop; Leonard Calabrese
Journal:  Nat Rev Rheumatol       Date:  2017-06-15       Impact factor: 20.543

5.  Ill-defined germinal centers and severely reduced plasma cells are histological hallmarks of lymphadenopathy in patients with common variable immunodeficiency.

Authors:  Susanne Unger; Maximilian Seidl; Annette Schmitt-Graeff; Joachim Böhm; Klaudia Schrenk; Claudia Wehr; Sigune Goldacker; Ruth Dräger; Barbara C Gärtner; Paul Fisch; Martin Werner; Klaus Warnatz
Journal:  J Clin Immunol       Date:  2014-05-02       Impact factor: 8.317

6.  Castleman's disease in carcinoma gall bladder.

Authors:  Vijay Waman Dhakre; Sanjay Nagral; Aditya Jayesh Nanavati
Journal:  BMJ Case Rep       Date:  2016-11-25

7.  [Dyspnoea, cough and B symptoms in a 40-year-old woman].

Authors:  A Wolfensberger; R Benz; E W Russi; M Tinguely; C Keller; B Gerber
Journal:  Internist (Berl)       Date:  2013-08       Impact factor: 0.743

8.  Does Kaposi's sarcoma predict multicentric Castleman disease in the presence of generalized lymphadenopathy?

Authors:  Homam Alkaied; Kassem Harris; Dany Elsayegh; Inga Khachaturova; Michael Awasum; Seema Varma
Journal:  Med Oncol       Date:  2011-04-07       Impact factor: 3.064

9.  Discordant lymphocyte-depleted classical Hodgkin's and peripheral T-cell lymphoma arising in a patient 11 years after diagnosis of multicentric Castleman's disease.

Authors:  Joonhong Park; Ji Eun Lee; Myungshin Kim; Jihyang Lim; Yonggoo Kim; Kyungja Han; Gyeongsin Park; Young Hee Jung; Sang Young Roh; Young Seon Hong
Journal:  Int J Hematol       Date:  2013-06-04       Impact factor: 2.490

Review 10.  Multicentric Castleman's disease: a challenging diagnosis.

Authors:  Györgyi Műzes; Ferenc Sipos; Judit Csomor; Lídia Sréter
Journal:  Pathol Oncol Res       Date:  2013-03-21       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.